Buchumschlag

Extracellular Vesicles miRNome Profiling Reveals miRNAs Engagement in Dysfunctional Lipid Metabolism, Chronic Inflammation and Liver Damage in Subjects With Metabolic Dysfunction‐Associated Steatotic Liver Disease

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Gian Paolo Caviglia, Elisabetta Casalone, Chiara Rosso, Serena Aneli, Alessandra Allione, Fabrizia Carli, Cristina Grange, Angelo Armandi, Chiara Catalano, Giovanni Birolo, Beatrice Foglia, Davide Giuseppe Ribaldone, Amalia Gastaldelli, Giuseppe Matullo, Elisabetta Bugianesi
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

MiRNome Profiling of Circulating Extracellular Vesicles in Patients With Chronic Hepatitis D Undergoing Pegylated Interferon Alpha Treatment
von: Gian Paolo Caviglia, et al.
Veröffentlicht: (2024)

Vitamin E in Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Stergios A. Polyzos, et al.
Veröffentlicht: (2024)

Uric Acid in Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Rong Wang, et al.
Veröffentlicht: (2026)

Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD
von: Salvatore Petta, et al.
Veröffentlicht: (2024)

Aspirin for Primary Prevention in Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Oguzhan Celik, et al.
Veröffentlicht: (2026)

The Impact of Liraglutide on Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease
von: Jae Eun So, et al.
Veröffentlicht: (2025)

Insights Into Intestinal Flora in Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Zechen Xin, et al.
Veröffentlicht: (2025)

Effects and Mechanisms of Stevioside on Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Kangjun Li, et al.
Veröffentlicht: (2026)

Platelet Functional Profile Is Altered in Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Marco Castelli, et al.
Veröffentlicht: (2025)

Oxidised Apolipoprotein Peptidome Characterises Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Gabriele Mocciaro, et al.
Veröffentlicht: (2025)

Maternal Dyslipidaemia Aggravates Offspring Metabolic Dysfunction–Associated Steatotic Liver Disease
von: Kamilla Pedersen, et al.
Veröffentlicht: (2026)

rs55959738 is Associated with Hepcidin in Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Niharika Samala, et al.
Veröffentlicht: (2025)

Response to “Aspirin for Primary Prevention in Metabolic Dysfunction‐Associated Steatotic Liver Disease”
von: Tsubasa Tsutsumi, et al.
Veröffentlicht: (2026)

An Insight into the Genetic Predisposition of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Africa
von: Yusuf Moolla, et al.
Veröffentlicht: (2024)

Metabolic Dysfunction‐Associated Steatotic Liver Disease After Hepatitis C Virus Cure
von: Chung‐Feng Huang, et al.
Veröffentlicht: (2025)

Effect of Statins and PCSK9 Inhibition on Metabolic Dysfunction–Associated Steatotic Liver Disease
von: Eleni Theocharidou, et al.
Veröffentlicht: (2025)

Platelet Proteomics: A Glimpse Into Metabolic Dysfunction‐Associated Steatotic Liver Disease Pathogenesis
von: Iulia Minciuna, et al.
Veröffentlicht: (2025)

Letter: Combination Therapies With Vitamin E for Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Stergios A. Polyzos, et al.
Veröffentlicht: (2024)

STING Activation in Various Cell Types in Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: JingJing Wang, et al.
Veröffentlicht: (2025)

Lean Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Wolf in Sheep's Clothing
von: Xixi Fang, et al.
Veröffentlicht: (2025)

Alcohol‐Related Liver Disease and Metabolic Dysfunction‐Associated Steatotic Liver Disease: Molecular Pathogenesis and Therapeutic Interventions
von: Yupin Tan, et al.
Veröffentlicht: (2025)

Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction–Associated Steatotic Liver Disease
von: Meng‐Lun Hsieh, et al.
Veröffentlicht: (2026)

The Gut‐Liver Axis in Metabolic Dysfunction‐Associated Steatotic Liver Disease: From Mechanistic Insights to Precision Therapeutics
von: Shaoliang Zhu, et al.
Veröffentlicht: (2026)

Comment on “Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction‐Associated Steatotic Liver Disease”
von: Klara Morzone, et al.
Veröffentlicht: (2026)

Liver Stiffness Directs Intrahepatic Cholesterol Accumulation Through YAP/TAZ in Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Na Young Lee, et al.
Veröffentlicht: (2026)

Young Adults Are at Highest Risk of Liver Fibrosis and Mortality Associated With Steatotic Liver Disease With Metabolic Dysfunction and Alcohol Consumption
von: Jesse Pustjens, et al.
Veröffentlicht: (2025)

Harnessing Gut Microbiome–Brain–Liver Crosstalk: Novel Therapeutic Strategies for Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Xingtao Zhao, et al.
Veröffentlicht: (2025)

Fat‐Corrected Non‐Gaussian Diffusion MRI for Liver Fibrosis Assessment in Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Omaïma Saïd, et al.
Veröffentlicht: (2025)

Comment on “Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction‐Associated Steatotic Liver Disease”
von: Hong‐Wei Zheng, et al.
Veröffentlicht: (2026)

The Association Between Metabolic Dysfunction‐Associated Steatotic Liver Disease and Change in Liver Stiffness in Patients With Chronic Hepatitis B
von: Lesley A. Patmore, et al.
Veröffentlicht: (2025)

Aspirin Use Does Not Significantly Reduce the Risk of Liver Fibrosis in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Linlin Yin, et al.
Veröffentlicht: (2025)

Endotoxin Markers Are Elevated in Adolescents With Obesity With and Without Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Alison M. Boone, et al.
Veröffentlicht: (2026)

Effect of Pemafibrate on Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationwide Multicenter Study
von: Yasuyuki Komiyama, et al.
Veröffentlicht: (2025)

Recent Advances in the Application of Machine Learning Models in Metabolic Dysfunction–Associated Steatotic Liver Disease
von: Fang Yang, et al.
Veröffentlicht: (2026)

Postbiotics as Antiinflammatory and Immune‐Modulating Bioactive Compounds in Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Yusuf Yilmaz
Veröffentlicht: (2024)

Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Soroor Owrangi, et al.
Veröffentlicht: (2024)

Prevalence and Characteristics of Hyperferritinemia in Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Meta‐Analysis
von: Matheus Souza, et al.
Veröffentlicht: (2026)

Prevalence and Predictors of Suspected Metabolic Dysfunction‐Associated Steatotic Liver Disease in Adolescents in the United States
von: Sheila L. Noon, et al.
Veröffentlicht: (2025)

Hemoglobin A1c is Associated With Advanced Liver Fibrosis in Psoriasis Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Hidenori Watabe, et al.
Veröffentlicht: (2026)

Evidence‐Based Clinical Practice Guidelines for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) 2026
von: Norio Akuta, et al.
Veröffentlicht: (2026)